Journal Home > Volume 1 , Issue 3
Cancer Innovation 2022, 1(3): 207-219 https://doi.org/10.1002/cai2.31
Review | Open Access | Issue | Published: 05 October 2022

Research progress in the establishment of pancreatic cancer models and preclinical applications

Show Author's Information Weizheng Wu1,  Kunming Wen1,  Yuxin Zhong2 ( )
Departments of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China
Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Keywords:
model, pancreatic cancer, pancreatic ductal adenocarcinoma, genetic engineering, heterotopic, orthotopic
Cite this article:
Wu W, Wen K, Zhong Y. Research progress in the establishment of pancreatic cancer models and preclinical applications. Cancer Innovation, 2022, 1(3): 207-219. https://doi.org/10.1002/cai2.31
Download citation
EndNote(RIS)
BibTeX

398

Views

17

Downloads

Citations

0

Crossref

N/A

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Pancreatic cancer (PC) is a highly malignant tumor in the digestive system. The transformation of tissue from normal to pancreatic intraepithelial neoplasm is driven by certain oncogenes, among which the mutation rate of the KRAS gene is as high as 90%. Currently, PC has limited treatment options, low therapeutic effects, and poor prognosis. Thus, more effective methods to combat PC are urgently needed. Some models that can more accurately reflect the biological behaviors and genomic characteristics of PC, such as its morphology, pathology, proliferation, and invasion, are being continuously developed. These include genetic engineering models, orthotopic xenograft models, and heterotopic xenograft models. Using these PC models, scientists have further verified promising drugs and potential therapeutic targets for PC treatment. This is of great significance for limiting the progression of PC with clinical intervention, improving patient outcomes, and improving survival rates.


menu
Abstract
Full text
Outline
About this article

Research progress in the establishment of pancreatic cancer models and preclinical applications

Show Author's information Weizheng Wu1, Kunming Wen1, Yuxin Zhong2 ( )
Departments of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China
Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Abstract

Pancreatic cancer (PC) is a highly malignant tumor in the digestive system. The transformation of tissue from normal to pancreatic intraepithelial neoplasm is driven by certain oncogenes, among which the mutation rate of the KRAS gene is as high as 90%. Currently, PC has limited treatment options, low therapeutic effects, and poor prognosis. Thus, more effective methods to combat PC are urgently needed. Some models that can more accurately reflect the biological behaviors and genomic characteristics of PC, such as its morphology, pathology, proliferation, and invasion, are being continuously developed. These include genetic engineering models, orthotopic xenograft models, and heterotopic xenograft models. Using these PC models, scientists have further verified promising drugs and potential therapeutic targets for PC treatment. This is of great significance for limiting the progression of PC with clinical intervention, improving patient outcomes, and improving survival rates.

Keywords: model, pancreatic cancer, pancreatic ductal adenocarcinoma, genetic engineering, heterotopic, orthotopic

References(89)

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
DOI Google Scholar
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
DOI Google Scholar
Sun D, Cao M, Li H, He S, Chen W. Cancer burden and trends in China: a review and comparison with Japan and South Korea. Chin J Cancer Res. 2020;32:129–39.
DOI Google Scholar
Hayashi AA‐O, Hong J, Iacobuzio‐Donahue CA‐O. The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol. 2021;18:469–81.
DOI Google Scholar
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet. 2020;395:2008–20.
DOI Google Scholar
Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17–33.
DOI Google Scholar
Mehra S, Deshpande N, Nagathihalli NA‐O. Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress. Cancers (Basel). 2021;13:4434.
DOI Google Scholar
Tsai PY, Lee MS, Jadhav U, Naqvi I, Madha S, Adler A, et al. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Proc Natl Acad Sci USA. 2021;118:e2003014118.
DOI Google Scholar
Hu Q, Qin Y, Ji S, Shi X, Dai W, Fan G, et al. MTAP deficiency‐induced metabolic reprogramming creates a vulnerability to cotargeting de novo purine synthesis and glycolysis in pancreatic cancer. Cancer Res. 2021;81:4964–80.
DOI Google Scholar
Takahashi R, Macchini M, Sunagawa M, Jiang Z, Tanaka T, Valenti G, et al. Interleukin‐1β‐induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte‐mediated immune suppression. Gut. 2021;70:330–41.
DOI Google Scholar
Shan T, Ma J, Ma Q, Guo K, Guo J, Li X, et al. β2‐AR‐HIF‐1α: a novel regulatory axis for stress‐induced pancreatic tumor growth and angiogenesis. Curr Mol Med. 2013;13:1023–34.
DOI Google Scholar
Duan W, Chen K, Jiang Z, Chen X, Sun L, Li J, et al. Desmoplasia suppression by metformin‐mediated AMPK activation inhibits pancreatic cancer progression. Cancer Lett. 2017;385:225–33.
DOI Google Scholar
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324–38.
DOI Google Scholar
DeCant BT, Principe DR, Guerra C, Pasca di Magliano M, Grippo PJ. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Front Physiol. 2014;5:464.
DOI Google Scholar
Gopinathan A, Morton JP, Jodrell DI, Sansom OJ. GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech. 2015;8:1185–1200.
DOI Google Scholar
Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol. 2013;7:232–47.
DOI Google Scholar
Hoang TT, Karkhoff‐Schweizer RR, Fau‐Kutchma AJ, Kutchma AJ, Fau‐Schweizer HP, Schweizer HP. A broad‐host‐range Flp‐FRT recombination system for site‐specific excision of chromosomally‐located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene. 1998;212:77–86.
DOI Google Scholar
Kranz A, Fu J, Duerschke K, Weidlich S, Naumann R, Stewart AF, et al. An improved Flp deleter mouse in C57Bl/6 based on Flpo recombinase. Genesis. 2010;48:512–20.
DOI Google Scholar
Wu J, Liu X, Nayak SG, Pitarresi JR, Cuitiño MC, Yu L, et al. Generation of a pancreatic cancer model using a Pdx1‐Flp recombinase knock‐in allele. PLoS One. 2017;12:e0184984.
DOI Google Scholar
Huynh AS, Abrahams DF, Fau‐Torres MS, Torres MS, Fau‐Baldwin MK, Baldwin MK, et al. Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One. 2011;6:e20330.
DOI Google Scholar
Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res. 2006;12:5277–87.
DOI Google Scholar
Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247–50.
DOI Google Scholar
Iwamura T, Fau‐Katsuki T, Katsuki T, Fau‐Ide K, Ide K. Establishment and characterization of a human pancreatic cancer cell line (SUIT‐2) producing carcinoembryonic antigen and carbohydrate antigen 19‐9. Jpn J Cancer Res. 1987;78:54–62.
Google Scholar
Higuchi T, Yokobori T, Naito T, Kakinuma C, Hagiwara S, Nishiyama M, et al. Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT‐2 pancreatic cancer mouse model. Oncol Lett. 2018;15:3091–9.
DOI Google Scholar
Hwang CI, Boj SF, Clevers H, Tuveson DA. Preclinical models of pancreatic ductal adenocarcinoma. J Pathol. 2016;238:197–204.
DOI Google Scholar
Choi SI, Jeon AR, Kim MK, Lee YS, Im JE, Koh JW, et al. Development of Patient‐Derived preclinical platform for metastatic pancreatic cancer: PDOX and a subsequent organoid model system using percutaneous biopsy samples. Front Oncol. 2019;9:875.
DOI Google Scholar
Iwamura T, Taniguchi S, Kitamura N, Yamanari H, Kojima A, Hidaka K, et al. Correlation between CA19‐9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT‐2). J Gastroenterol Hepatol. 1992;7:512–9.
DOI Google Scholar
Taniuchi K, Furihata M, Hanazaki K, Saito M, Saibara T. IGF2BP3‐mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. Oncotarget. 2014;5:6832–45.
DOI Google Scholar
Tanaka C, Furihata K, Naganuma S, Ogasawara M, Yoshioka R, Taniguchi H, et al. Establishment of a mouse model of pancreatic cancer using human pancreatic cancer cell line S2‐013‐derived organoid. Hum Cell. 2022;35:735–44.
DOI Google Scholar
Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476–84.
DOI Google Scholar
Colvin EK, Scarlett CJ. A historical perspective of pancreatic cancer mouse models. Semin Cell Dev Biol. 2014;27:96–105.
DOI Google Scholar
Li J, Qian W, Qin T, Xiao Y, Cheng L, Cao J, et al. Mouse‐derived allografts: a complementary model to the KPC mice on researching pancreatic cancer in vivo. Comput Struct Biotechnol J. 2019;17:498–506.
DOI Google Scholar
Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 2003;26:e89–98.
DOI Google Scholar
Loukopoulos P, Kanetaka K, Fau‐Takamura M, Takamura M, Fau‐Shibata T, Shibata T, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29:193–203.
DOI Google Scholar
Miao J, Ying B, Li R, Tollefson A, Spencer J, Wold W, et al. Characterization of an N‐terminal non‐core domain of RAG1 gene disrupted syrian hamster model generated by CRISPR Cas9. Viruses. 2018;10:243.
DOI Google Scholar
Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, et al. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor‐specific immunity. Clin Cancer Res. 2012;18:6679–89.
DOI Google Scholar
Wang P, Li X, Wang J, Gao D, Li Y, Li H, et al. Re‐designing Interleukin‐12 to enhance its safety and potential as an anti‐tumor immunotherapeutic agent. Nat Commun. 2017;8:1395.
DOI Google Scholar
Yunis AA, Fau‐Arimura GK, Arimura GK, Fau‐Russin DJ, Russin DJ. Human pancreatic carcinoma (MIA PaCa‐2) in continuous culture: sensitivity to asparaginase. Int J Cancer. 1977;19:128–35.
DOI Google Scholar
Miao JX, Wang JY, Li HZ, Guo HR, Dunmall L, Zhang ZX, et al. Promising xenograft animal model recapitulating the features of human pancreatic cancer. World J Gastroenterol. 2020;26:4802–16.
DOI Google Scholar
Lee LM, Seftor EA, Fau‐Bonde G, Bonde G, Fau‐Cornell RA, Cornell RA, et al. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn. 2005;233:1560–70.
DOI Google Scholar
Park JT, Leach SD. Zebrafish model of KRAS‐initiated pancreatic cancer. Anim Cells Syst (Seoul). 2018;22:353–9.
DOI Google Scholar
Di Franco G, Usai A, Funel N, Palmeri M, Montesanti I, Bianchini M, et al. Use of zebrafish embryos as avatar of patients with pancreatic cancer: a new xenotransplantation model towards personalized medicine. World J Gastroenterol. 2020;26:2792–809.
DOI Google Scholar
Gou S, Cui P, Fau‐Li X, Li X, Fau‐Shi P, Shi P, et al. Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013;8:e63969.
DOI Google Scholar
Algire C, Amrein L, Fau‐Zakikhani M, Zakikhani M, Fau‐Panasci L, Panasci L, et al. Metformin blocks the stimulative effect of a high‐energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010;17:351–60.
DOI Google Scholar
Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7:40767–80.
DOI Google Scholar
Qian W, Li J, Chen K, Jiang Z, Cheng L, Zhou C, et al. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci. 2018;208:253–61.
DOI Google Scholar
Stern PH, Fau‐Hoffman RM, Hoffman RM. Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro. 1984;20:663–70.
DOI Google Scholar
Kaiser P. Methionine dependence of cancer. Biomolecules. 2020;10:568.
DOI Google Scholar
Guo H, Lishko VK, Fau‐Herrera H, Herrera H, Fau‐Groce A, Groce A, et al. Therapeutic tumor‐specific cell cycle block induced by methionine starvation in vivo. Cancer Res. 1993;53:5676–9.
Google Scholar
Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, et al. Human tumors are methionine dependent in vivo. Anticancer Res. 1995;15:717–8.
Google Scholar
Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, et al. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res. 1999;5:2157–63.
Google Scholar
Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S, et al. Repression of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer. 2007;7:108.
DOI Google Scholar
Yamamoto J, Miyake K, Han Q, Tan Y, Inubushi S, Sugisawa N, et al. Oral recombinant methioninase increases TRAIL receptor‐2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020;492:174–84.
DOI Google Scholar
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
DOI Google Scholar
Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012;2012:283181.
DOI Google Scholar
Chen J, Green J, Yurdagul A, Jr., Albert P, McInnis MC, et al. αvβ3 integrins mediate flow‐induced NF‐κB activation, proinflammatory gene expression, and early atherogenic inflammation. Am J Pathol. 2015;185:2575–89.
DOI Google Scholar
Debreli Coskun M, Sudha T, Bharali DJ, Celikler S, Davis PJ, Mousa SA. alphavbeta3 integrin antagonists enhance chemotherapy response in an orthotopic pancreatic cancer model. Front Pharmacol. 2020;11:95.
DOI Google Scholar
Fuchs D, Daniel V, Fau‐Sadeghi M, Sadeghi M, Fau‐Opelz G, Opelz G, et al. Salinomycin overcomes ABC transporter‐mediated multidrug and apoptosis resistance in human leukemia stem cell‐like KG‐1a cells. Biochem Biophys Res Commun. 2010;394:1098–104.
DOI Google Scholar
Verdoodt B, Vogt M, Fau‐Schmitz I, Schmitz I, Fau‐Liffers S‐T, Liffers ST, et al. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One. 2012;7:e44132.
DOI Google Scholar
Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106:99–106.
DOI Google Scholar
Schenk M, Aykut B, Teske C, Giese NA, Weitz J, Welsch T. Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Cancer Lett. 2015;358:161–9.
DOI Google Scholar
Tan MH, Fau‐Shimano T, Shimano T, Fau‐Chu TM, Chu TM. Differential localization of human pancreas cancer‐associated antigen and carcinoembryonic antigen in homologous pancreatic tumoral xenograft. J Natl Cancer Inst. 1981;67:563–9.
Google Scholar
Daman Z, Faghihi H, Montazeri H. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Dev Ind Pharm. 2018;44:1434–42.
DOI Google Scholar
Li M, Wang MM, Guo XW, Wu CY, Li DR, Zhang X, et al. Different survival benefits of Chinese medicine for pancreatic cancer: how to choose?Chin J Integr Med. 2018;24:178–84.
DOI Google Scholar
Lau ST, Lin ZX, Fau‐Zhao M, Zhao M, Fau‐Leung PS, Leung PS. Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytother Res. 2008;22:477–86.
DOI Google Scholar
Yang H, Tong Z, Shen L, Sun YU, Hoffman RM, Huang J. Brucea javanica increases survival and enhances gemcitabine efficacy in a patient‐derived orthotopic xenograft (PDOX) mouse model of pancreatic cancer. Anticancer Res. 2020;40:4969–78.
DOI Google Scholar
Kawaguchi K, Igarashi K, Miyake K, Lwin TM, Miyake M, Kiyuna T, et al. MEK inhibitor trametinib in combination with gemcitabine regresses a patient‐derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Tissue Cell. 2018;52:124–8.
DOI Google Scholar
Kawaguchi K, Miyake K, Han Q, Li S, Tan Y, Igarashi K, et al. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine‐resistance and regresses a patient‐derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. Cell Cycle. 2018;17:868–73.
DOI Google Scholar
Kaur S, Kumar S, Fau‐Momi N, Momi N, Fau‐Sasson AR, Sasson AR, et al. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607–20.
DOI Google Scholar
Kyriazis AA, Fau‐Kyriazis AP, Kyriazis AP, Fau‐Sternberg CN, Sternberg CN, Fau‐Sloane NH, et al. Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan‐2 in tissue culture and the nude mouse. Cancer Res. 1986;46:5810–5.
Google Scholar
Wu G, Maharjan S, Kim D, Kim JN, Park BK, Koh H, et al. A novel monoclonal antibody targets Mucin1 and attenuates growth in pancreatic cancer model. Int J Mol Sci. 2018;19:2004.
DOI Google Scholar
Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 2017;23:1670–8.
DOI Google Scholar
Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, et al. Identification and characterization of AES‐135, a hydroxamic acid‐based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer. J Med Chem. 2019;62:2651–65.
DOI Google Scholar
Peters HL, Tuli A, Wang X, Liu C, Pan Z, Ouellette MM, et al. Relevance of amyloid precursor‐like protein 2 C‐terminal fragments in pancreatic cancer cells. Int J Oncol. 2012;41:1464–74.
DOI Google Scholar
Peters HL, Yan Y, Fau‐Nordgren TM, Nordgren TM, Fau‐Cutucache CE, Cutucache CE, et al. Amyloid precursor‐like protein 2 suppresses irradiation‐induced apoptosis in Ewing sarcoma cells and is elevated in immune‐evasive Ewing sarcoma cells. Cancer Biol Ther. 2013;14:752–60.
DOI Google Scholar
Pandey P, Sliker B, Peters HL, Tuli A, Herskovitz J, Smits K, et al. Amyloid precursor protein and amyloid precursor‐like protein 2 in cancer. Oncotarget. 2016;7:19430–44.
DOI Google Scholar
Pandey P, Rachagani S, Das S, Seshacharyulu P, Sheinin Y, Naslavsky N, et al. Amyloid precursor‐like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. Oncotarget. 2015;6:2064–75.
DOI Google Scholar
Poelaert BJ, Knoche SM, Larson AC, Pandey P, Seshacharyulu P, Khan N, et al. Amyloid precursor‐like protein 2 expression increases during pancreatic cancer development and shortens the survival of a spontaneous mouse model of pancreatic cancer. Cancers (Basel). 2021;13:1535.
DOI Google Scholar
Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK, Reynolds CP, et al. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol. 2016;173:3292–306.
DOI Google Scholar
Gupta N, Miyauchi S, Martindale RG, Herdman AV, Podolsky R, Miyake K, et al. Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta. 2005;1741:215–23.
DOI Google Scholar
Babu E, Bhutia YD, Ramachandran S, Gnanaprakasam JP, Prasad PD, Thangaraju M, et al. Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer. Biochem J. 2015;469:17–23.
DOI Google Scholar
Gupta N, Prasad PD, Ghamande S, Moore‐Martin P, Herdman AV, Martindale RG, et al. Up‐regulation of the amino acid transporter ATB(0,+) (SLC6A14) in carcinoma of the cervix. Gynecol Oncol. 2006;100:8–13.
DOI Google Scholar
Schniers BK, Wachtel MS, Sharma M, Korac K, Rajasekaran D, Yang S, et al. Deletion of Slc6a14 reduces cancer growth and metastatic spread and improves survival in KPC mouse model of spontaneous pancreatic cancer. Biochem J. 2022;479:719–30.
DOI Google Scholar
Song W, Tian C, Wang K, Zhang RJ, Zou SB. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: a systematic review and meta‐analysis. PLoS One. 2017;12:e0178762.
DOI Google Scholar
Corbett TH, Fau‐Roberts BJ, Roberts BJ, Fau‐Leopold WR, Leopold WR, Fau‐Peckham JC, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717–26.
Google Scholar
Boone BA, Murthy P, Miller‐Ocuin JL, Liang X, Russell KL, Loughran P, et al. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Ann Hematol. 2019;98:1603–10.
DOI Google Scholar
King H, Thillai K, Whale A, Arumugam P, Eldaly H, Kocher HM, et al. PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration. Sci Rep. 2017;7:42575.
DOI Google Scholar
Lieber M, Fau‐Mazzetta J, Mazzetta J, Fau‐Nelson‐Rees W, Nelson‐Rees W, Fau‐Kaplan M, et al. Establishment of a continuous tumor‐cell line (panc‐1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741–7.
DOI Google Scholar
Xu L, Faruqu FN, Lim YM, Lim KY, Liam‐Or R, Walters AA, et al. Exosome‐mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco‐regional treatment. Biomaterials. 2021;264:120369.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 18 June 2022
Accepted: 22 August 2022
Published: 05 October 2022
Issue date: October 2022

Copyright

© 2022 The Authors.

Acknowledgements

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Return